.

Non-Responders to Cancer Immunotherapy May Lack Essential Immune Cells

Cancer immunotherapy is a type of treatment that uses the body’s own immune system to fight cancer. It has been used to treat many types of cancer, including melanoma, lung cancer, and lymphoma. However, not all patients respond to this type of treatment. A new study has found that non-responders may lack essential immune cells that are necessary for the therapy to be effective.

The study, which was published in the journal Nature Medicine, looked at the immune cells of patients who responded to immunotherapy and those who did not. The researchers found that the non-responders had significantly lower levels of a type of immune cell called CD8+ T cells. These cells are important for recognizing and attacking cancer cells.

The researchers also found that the non-responders had lower levels of a type of immune cell called CD4+ T cells. These cells help to activate and regulate the immune system.

The findings suggest that the lack of these essential immune cells may be a major factor in why some patients do not respond to immunotherapy. The researchers hope that this discovery will lead to new treatments that can help to boost the levels of these cells in non-responders, allowing them to benefit from immunotherapy.

The study is an important step forward in understanding why some patients do not respond to immunotherapy. It could lead to new treatments that can help to improve the effectiveness of this type of cancer treatment.

#Cancer #Immunotherapy #CD8+Tcells #CD4+Tcells #NonResponders #NatureMedicine #ImmuneSystem #Treatments

Summary: A new study has found that non-responders to cancer immunotherapy may lack essential immune cells that are necessary for the therapy to be effective. The study looked at the immune cells of patients who responded to immunotherapy and those who did not and found that the non-responders had significantly lower levels of CD8+ T cells and CD4+ T cells. The findings suggest that the lack of these essential immune cells may be a major factor in why some patients do not respond to immunotherapy and could lead to new treatments that can help to boost the levels of these cells in non-responders, allowing them to benefit from immunotherapy.